High-Sensitivity Cardiac Troponin T and Cardiovascular Risk After Ischemic Stroke or Transient Ischemic Attack.

Background

High-sensitivity cardiac troponin T (hs-cTnT) is associated with cardiovascular disease (CVD) risk in general and various high-risk populations.

Objectives

The purpose of this study was to precisely characterize the association of hs-cTnT with CVD risk in patients following acute ischemic stroke or transient ischemic attack.

Methods

We conducted post hoc analyses of data from the STROKE-CARD trial (NCT02156778), a pragmatic randomized controlled trial of a disease management program in patients with acute ischemic stroke or transient ischemic attack (ABCD

Results

Among 1,687 patients (mean age, 69.3 ± 13.7 years; 40.7% female), hs-cTnT was detectable in 80.7%. Median hs-cTnT was 10 ng/L (IQR: 6-18 ng/L). Over a median follow-up of 12.1 months, 110 patients had a CVD event. The association of hs-cTnT level with CVD risk was of log-linear shape, with a multivariable-adjusted HR of 1.40 (95% CI: 1.15-1.70;

Conclusions

High hs-cTnT is associated with increased CVD risk in ischemic stroke and transient ischemic attack patients.

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The STROKE-CARD trial was financially supported by the University Hospital (Tirol Kliniken), Tyrolean Health Insurance Company (TGKK), the Tyrol Health Care Funds (TGF), and unrestricted research grants from Boehringer Ingelheim, Bayer Healthcare, Nstim Services, and Sanofi. Komarek, Lang, Knoflach, and Kiechl were supported by VASCage-Research Centre on Clinical Stroke Research. VASCage is a COMET Centre within the Competence Centers for Excellent Technologies (COMET) program and funded by the Federal Ministry for Climate Action, Environment, Energy, Mobility, Innovation and Technology, the Federal Ministry of Labor and Economy, and the federal states of Tyrol, Salzburg, and Vienna. COMET is managed by the Austrian Research Promotion Agency (Österreichische Forschungsförderungsgesellschaft). FFG Project number: 898252. Prof P. Willeit reports personal fees from Novartis Pharmaceuticals outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: This study suggests a graded association between elevated high-sensitivity cardiac troponin T concentration and cardiovascular risk in patients after ischemic stroke or transient ischemic attack. TRANSLATIONAL OUTLOOK: Future research is needed to clarify whether patients with elevated high-sensitivity cardiac troponin T benefit from additional targeted preventive measures, including a tailored cardiac workup.